PBI-Gordon’s Strategic Power Play: Tapping an Elanco Veteran to Scale its Animal Health Ambitions

SHAWNEE, KS – June 03, 2026 – In a move that underscores a deliberate and aggressive expansion strategy, PBI-Gordon Companies, Inc. has appointed Kent Luther, a 30-year animal health industry veteran, as the new Vice President of Sales and Commercial Operations for its subsidiary, Pegasus Laboratories. The announcement is far more than a routine executive shuffle; it represents a critical piece of PBI-Gordon's multi-year plan to solidify its leadership in the booming, multi-billion-dollar animal health sector.

Luther, who previously led a nationwide sales organization as Senior Vice President at industry giant Elanco, is tasked with building the commercial engine to capitalize on PBI-Gordon's significant investments. His appointment follows a period of explosive growth for the 100% employee-owned company, which has seen nearly 60% sales growth and a 150% increase in research and development spending. This strategic hire signals that PBI-Gordon is now ready to translate its R&D firepower and recent acquisitions into significant market share.

The Engine for an Expanding Pipeline

Luther’s arrival is not happening in a vacuum. It follows PBI-Gordon's largest-ever transaction in May 2025: the acquisition of Irish therapeutic solutions company TriviumVet. That deal brought innovative treatments, like the first FDA-conditionally approved drug for a common feline heart condition, into the Pegasus Laboratories portfolio. With a rapidly expanding pipeline of specialized pharmaceuticals, the challenge shifts from development to commercialization—a challenge Luther is uniquely qualified to meet.

"Kent is a proven commercial leader with deep animal health experience and a strong track record of building high-performing teams, strengthening customer partnerships, and delivering growth," said Joyce J. Lee, Senior Vice President and General Manager of Pegasus Laboratories. "As PBI-Gordon Companies accelerates its strategic growth plan, Kent's experience scaling large commercial organizations and launching innovative products makes him exactly the right leader to expand Pegasus Laboratories' commercial capabilities and continue to drive our next phase of growth."

His role will be pivotal in steering the commercial strategy for Pegasus’s two main product lines: PRN® Pharmacal, which focuses on specialized therapies for unmet needs, and Sē•Qual™, its generic drug line. This dual approach allows the company to innovate at the cutting edge while also providing cost-effective solutions to the veterinary market.

A Microcosm of Industry Shifts: Specialization and the Rise of the CDMO

Luther’s transition from a behemoth like Elanco to the more specialized, agile environment of Pegasus Laboratories reflects a broader evolution within the animal health industry. As the trend of “pet humanization” continues, owners are demanding and willing to pay for more sophisticated treatments for their companion animals, particularly for chronic conditions. This has created a fertile market for companies like Pegasus that focus on niche, high-impact pharmaceuticals rather than competing on all fronts.

Furthermore, Pegasus operates a sophisticated dual model. Beyond its own product lines, it functions as a full-service Contract Development and Manufacturing Organization (CDMO). In this capacity, it provides the critical infrastructure and expertise for other animal health companies to bring their own products from concept to commercialization. This CDMO segment is a high-growth area, as it allows both startups and established players to outsource complex manufacturing and navigate stringent regulatory hurdles, accelerating innovation across the entire sector. The global veterinary CDMO market was valued at over $5.8 billion in 2022 and is on a steep growth trajectory, a trend Pegasus is well-positioned to capitalize on.

By hiring a commercial leader with experience launching products at scale, PBI-Gordon is signaling its intent to not only grow its own brands but also to become an indispensable manufacturing and development partner for the wider industry.

The Employee-Owned Advantage in a Competitive Talent War

Attracting an executive of Luther’s caliber from a publicly traded giant is a significant coup, and it shines a spotlight on PBI-Gordon’s most unique characteristic: its 100% employee-owned structure. Operating under an Employee Stock Ownership Plan (ESOP) since 1994, the company fosters a culture where every employee has a direct stake in long-term success. This model stands in stark contrast to the quarterly pressures of the public market and can be a powerful magnet for leaders seeking to build lasting value.

In an industry marked by consolidation and intense competition for talent, the employee-owned model offers a distinct competitive advantage. It aligns personal and corporate success, fostering a collaborative environment that, as the press release notes, matches Luther’s own leadership style. This cultural alignment is critical when integrating new leadership and executing an ambitious growth strategy. The company's ability to attract and retain top-tier talent is a direct result of this long-term, shared-ownership mindset, providing the stability needed to pursue a multi-year strategy of heavy R&D investment and strategic acquisitions.

As PBI-Gordon continues to navigate the dynamic animal health market—a market projected to grow from nearly $35 billion in 2025—its blend of strategic acquisitions, deep R&D investment, a unique cultural model, and now, top-tier commercial leadership, positions it as a formidable player. Kent Luther's new role is not just about selling products; it is about steering a well-funded, highly motivated, and strategically positioned company into its next chapter of significant growth.